Answers are grounded in this paper and cite their sources.
Radiotheranostics has achieved clinical maturity, yet preclinical development remains reliant on animal studies. Direct, dynamic measurement of radionuclide distribution offers a distinctive opportunity to develop quantitative New Approach Methodology (NAM) frameworks. We propose integrating human-relevant models, radionuclide sensing, historical biodistribution data and AI-assisted computational prediction. Fit-for-purpose validation, defined contexts of use and domains of applicability, and quantified predictive uncertainty could support reliable translational decisions and enable development beyond animal-first pipelines.
No takes yet. Share an insight, caveat, or question.
Hards et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: